Posted: Monday, October 31, 2022
In a recent abstract presented at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 01), researchers examined the effects of combining stereotactic body radiation and sorafenib therapy for patients with advanced hepatocellular carcinoma. Laura Ann Dawson, MD, FASTRO, of the Princess Margaret Cancer Centre, University of Toronto, and colleagues assessed the clinical impact of this combination and reported improvements in several outcome measures.
“Adding radiation therapy to systemic therapy delayed tumor progression and lengthened survival, without an increase in side effects. In all regards, the combination of radiation therapy and sorafenib appears more effective than the drug on its own,” said Dr. Dawson in a recent ASTRO press release.
A total of 177 eligible patients were randomly assigned to treatment groups. Patients were administered 400 mg of sorafenib (n = 92) twice daily followed by 200 mg; the dosage was increased to 400 mg after 28 days, if appropriate. In the radiation-plus-drug group (n = 85), patients were administered radiation at 27.5 to 50 Gy in five fractions and sorafenib dose individualization based on dose constraints.
Key findings revealed 153 overall survival events, with trending improvements in median overall survival from 12.3 months (90% confidence interval [CI] = 10.6–14.3) with sorafenib alone to 15.8 months (90% CI = 11.4–19.2) with the combination therapy (P = .0554). After the investigators adjusted for specific factors, there were statistical differences in overall survival between the groups (hazard ratio [HR] = 0.72, 95% CI = 0.52%–0.99%, two-sided Cox P = .042). Median progression-free survival was also improved from 5.5 months (95% CI = 3.46.3) to 9.2 months (95% CI = 7.5–11.9) with sorafenib alone and the combination therapy, respectively, (HR = 0.55, 95% CI = 0.40–0.75, two-sided Cox P = .0001).
Disclosure: To view Dr. Dawson’s disclosures, visit plan.core-apps.com.